you must be on the PH's payroll to write such drivel. Chow has...

First 590 Last

Share
Profile

Follow
Milcom

716 Posts.

159

15/02/24

12:37

Post #: 72422073
Share

Originally posted by dalts66: ↑

I think you need to do a bit more research into all of those ideas you posted. What was that bonus and when did it stop? Its all explained in the CHM announcements.That is how poaching high flyer leadership works in the US. Using her experience in CarT development has saved CHM more in time and money than any bonus she received. CarT is a very expensive treatment. Any waste of drug or time becomes very expensive. She knows what endpoints are needed for the FDA and she knows how to achieve these efficiently.

If the results gained from the Phase 1A trial into GBM and be repeated in the Phase 1B an accelerated pathway to approval is pretty much a given. And those results were achieved with the drug being used as a 4th line of treatment. The phase 1B has moved that to second line of treatment. There is no SOC for GBM. CHM are targeting a cancer with an unmet need, and no cure. The results from the Phase 1A were superior to whats available now.

Expand

you must be on the PH's payroll to write such drivel.

Chow has been there since 2020, She was the COO before.
Her salary increased from $758k to $849k from '22 to '23. Already way overpaid for where this company is in its lifecycle. Total package last FY was $3 million. Rort

The massive bonuses saved money, what a joke.

11 patients dosed, only 6 showed disease control and only one more than current median survival rate and that could be due to any other factors. Absolutely nothing to suggest CLTX will become SoC.

Shortfall, couldn't place the shortfall, most of the monies goes to pay staff. What will Chow's bonus be this year eh and what for

What's the bet the next raising will be a con note or facility which will be the true beginning of the end

Last edited by Milcom: 15/02/24

CHM Price at posting: 2.6¢ Sentiment: Sell Disclosure: Not Held
7 Upvote

0 Great analysis

Reply